Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Amneal Pharmaceuticals, Inc.

< Previous 1 2 3 Next >
Amneal to Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Reports Third Quarter 2024 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Report Third Quarter 2024 Results on November 8, 2024
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Reports Second Quarter 2024 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Report Second Quarter 2024 Results on August 9, 2024
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Releases 2023 Environmental, Social and Governance Report
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Participate at Upcoming Investor Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Reports First Quarter 2024 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Report First Quarter 2024 Results on May 3, 2024
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Participate at Upcoming Investor Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.